Premium
Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 ( CYP ) 2D6 Genotype and Atomoxetine Therapy
Author(s) -
Brown Jacob T.,
Bishop Jeffrey R.,
Sangkuhl Katrin,
Nurmi Erika L.,
Mueller Daniel J.,
Dinh Jean C.,
Gaedigk Andrea,
Klein Teri E.,
Caudle Kelly E.,
McCracken James T.,
Leon Jose,
Leeder J. Steven
Publication year - 2019
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1409
Subject(s) - atomoxetine , cyp2d6 , pharmacogenetics , pharmacology , guideline , cytochrome p450 , medicine , genotype , atomoxetine hydrochloride , attention deficit hyperactivity disorder , psychiatry , biology , genetics , methylphenidate , metabolism , pathology , gene
Atomoxetine is a nonstimulant medication used to treat attention‐deficit/hyperactivity disorder (ADHD). Cytochrome P450 ( CYP ) 2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP 2D6 genotype (updates at www.cpicpgx.org ).